US Stock MarketDetailed Quotes

ANTX AN2 Therapeutics

Watchlist
  • 1.430
  • -0.050-3.38%
Close Dec 13 16:00 ET
  • 1.430
  • 0.0000.00%
Post 20:01 ET
42.73MMarket Cap-0.72P/E (TTM)

AN2 Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-1.75%-12.01M
-12.16%-14.38M
-51.72%-17.59M
-59.25%-53.29M
-123.46%-17.07M
-24.38%-11.8M
-33.65%-12.82M
-72.00%-11.6M
-63.36%-33.46M
15.07%-7.64M
Net income from continuing operations
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-58.05%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-100.17%-15.32M
-90.11%-40.96M
-56.95%-11.84M
Other non cash items
----
----
----
-31.17%53K
--0
-35.00%13K
10.53%21K
5.56%19K
--77K
--20K
Change In working capital
-112.76%-431K
-190.05%-1.33M
-209.40%-2.27M
56.91%5.83M
-135.50%-1.1M
297.88%3.38M
322.78%1.48M
366.29%2.08M
11,518.75%3.72M
262.13%3.09M
-Change in prepaid assets
-1,633.33%-322K
31.93%-795K
49.46%1.11M
38.86%-1.03M
-287.05%-621K
-96.69%21K
43.79%-1.17M
231.10%742K
-20.98%-1.68M
131.92%332K
-Change in payables and accrued expense
-134.46%-826K
-129.03%-774K
-324.33%-3.03M
14.14%6.25M
-105.67%-168K
1,617.09%2.4M
152.46%2.67M
-16.02%1.35M
489.13%5.47M
343.23%2.97M
-Change in other current liabilities
-25.31%717K
1,238.10%239K
-1,721.05%-346K
896.10%613K
-1,435.00%-307K
4,900.00%960K
-10.53%-21K
-5.56%-19K
---77K
---20K
Cash from discontinued investing activities
Operating cash flow
-1.75%-12.01M
-12.16%-14.38M
-51.72%-17.59M
-59.25%-53.29M
-123.46%-17.07M
-24.38%-11.8M
-33.65%-12.82M
-72.00%-11.6M
-63.36%-33.46M
15.07%-7.64M
Investing cash flow
Cash flow from continuing investing activities
129.97%18.72M
108.96%16.46M
141.48%26.29M
-98.79%-43.28M
-93.06%420K
-2,595.81%-62.46M
119.95%7.88M
-22.11%10.89M
56.48%-21.77M
-3.06%6.06M
Net investment purchase and sale
129.97%18.72M
108.96%16.46M
141.48%26.29M
-98.79%-43.28M
-93.06%420K
-2,595.81%-62.46M
119.95%7.88M
-22.11%10.89M
56.48%-21.77M
-3.06%6.06M
Cash from discontinued investing activities
Investing cash flow
129.97%18.72M
108.96%16.46M
141.48%26.29M
-98.79%-43.28M
-93.06%420K
-2,595.81%-62.46M
119.95%7.88M
-22.11%10.89M
56.48%-21.77M
-3.06%6.06M
Financing cash flow
Cash flow from continuing financing activities
-99.97%23K
0
75.38%349K
20.81%84.99M
-321K
660,760.00%66.07M
165.39%19.05M
-99.69%199K
-10.42%70.36M
0
Net common stock issuance
--0
----
----
20.13%84.53M
---321K
658,100.00%65.8M
----
----
--70.37M
--0
Proceeds from stock option exercised by employees
-91.35%23K
--0
75.38%349K
4,327.27%465K
--0
--266K
--0
1,909.09%199K
-200.00%-11K
--0
Cash from discontinued financing activities
Financing cash flow
-99.97%23K
--0
75.38%349K
20.81%84.99M
---321K
660,760.00%66.07M
165.39%19.05M
-99.69%199K
-10.42%70.36M
--0
Net cash flow
Beginning cash position
-34.41%26.77M
-7.55%24.69M
-42.51%15.65M
125.01%27.22M
13.24%32.62M
0.48%40.81M
-67.63%26.71M
125.01%27.22M
197.22%12.1M
82.14%28.8M
Current changes in cash
182.17%6.74M
-85.28%2.08M
1,873.73%9.05M
-176.52%-11.57M
-971.95%-16.97M
30.62%-8.2M
133.66%14.1M
-100.72%-510K
88.39%15.12M
57.40%-1.58M
End cash Position
2.72%33.5M
-34.41%26.77M
-7.55%24.69M
-42.51%15.65M
-42.51%15.65M
13.24%32.62M
0.48%40.81M
-67.63%26.71M
125.01%27.22M
125.01%27.22M
Free cash flow
-1.75%-12.01M
-12.16%-14.38M
-51.72%-17.59M
-59.25%-53.29M
-123.46%-17.07M
-24.38%-11.8M
-33.65%-12.82M
-72.00%-11.6M
-63.36%-33.46M
15.07%-7.64M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -1.75%-12.01M-12.16%-14.38M-51.72%-17.59M-59.25%-53.29M-123.46%-17.07M-24.38%-11.8M-33.65%-12.82M-72.00%-11.6M-63.36%-33.46M15.07%-7.64M
Net income from continuing operations 23.70%-12.75M8.66%-14.44M-8.44%-16.62M-58.05%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-100.17%-15.32M-90.11%-40.96M-56.95%-11.84M
Other non cash items -------------31.17%53K--0-35.00%13K10.53%21K5.56%19K--77K--20K
Change In working capital -112.76%-431K-190.05%-1.33M-209.40%-2.27M56.91%5.83M-135.50%-1.1M297.88%3.38M322.78%1.48M366.29%2.08M11,518.75%3.72M262.13%3.09M
-Change in prepaid assets -1,633.33%-322K31.93%-795K49.46%1.11M38.86%-1.03M-287.05%-621K-96.69%21K43.79%-1.17M231.10%742K-20.98%-1.68M131.92%332K
-Change in payables and accrued expense -134.46%-826K-129.03%-774K-324.33%-3.03M14.14%6.25M-105.67%-168K1,617.09%2.4M152.46%2.67M-16.02%1.35M489.13%5.47M343.23%2.97M
-Change in other current liabilities -25.31%717K1,238.10%239K-1,721.05%-346K896.10%613K-1,435.00%-307K4,900.00%960K-10.53%-21K-5.56%-19K---77K---20K
Cash from discontinued investing activities
Operating cash flow -1.75%-12.01M-12.16%-14.38M-51.72%-17.59M-59.25%-53.29M-123.46%-17.07M-24.38%-11.8M-33.65%-12.82M-72.00%-11.6M-63.36%-33.46M15.07%-7.64M
Investing cash flow
Cash flow from continuing investing activities 129.97%18.72M108.96%16.46M141.48%26.29M-98.79%-43.28M-93.06%420K-2,595.81%-62.46M119.95%7.88M-22.11%10.89M56.48%-21.77M-3.06%6.06M
Net investment purchase and sale 129.97%18.72M108.96%16.46M141.48%26.29M-98.79%-43.28M-93.06%420K-2,595.81%-62.46M119.95%7.88M-22.11%10.89M56.48%-21.77M-3.06%6.06M
Cash from discontinued investing activities
Investing cash flow 129.97%18.72M108.96%16.46M141.48%26.29M-98.79%-43.28M-93.06%420K-2,595.81%-62.46M119.95%7.88M-22.11%10.89M56.48%-21.77M-3.06%6.06M
Financing cash flow
Cash flow from continuing financing activities -99.97%23K075.38%349K20.81%84.99M-321K660,760.00%66.07M165.39%19.05M-99.69%199K-10.42%70.36M0
Net common stock issuance --0--------20.13%84.53M---321K658,100.00%65.8M----------70.37M--0
Proceeds from stock option exercised by employees -91.35%23K--075.38%349K4,327.27%465K--0--266K--01,909.09%199K-200.00%-11K--0
Cash from discontinued financing activities
Financing cash flow -99.97%23K--075.38%349K20.81%84.99M---321K660,760.00%66.07M165.39%19.05M-99.69%199K-10.42%70.36M--0
Net cash flow
Beginning cash position -34.41%26.77M-7.55%24.69M-42.51%15.65M125.01%27.22M13.24%32.62M0.48%40.81M-67.63%26.71M125.01%27.22M197.22%12.1M82.14%28.8M
Current changes in cash 182.17%6.74M-85.28%2.08M1,873.73%9.05M-176.52%-11.57M-971.95%-16.97M30.62%-8.2M133.66%14.1M-100.72%-510K88.39%15.12M57.40%-1.58M
End cash Position 2.72%33.5M-34.41%26.77M-7.55%24.69M-42.51%15.65M-42.51%15.65M13.24%32.62M0.48%40.81M-67.63%26.71M125.01%27.22M125.01%27.22M
Free cash flow -1.75%-12.01M-12.16%-14.38M-51.72%-17.59M-59.25%-53.29M-123.46%-17.07M-24.38%-11.8M-33.65%-12.82M-72.00%-11.6M-63.36%-33.46M15.07%-7.64M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Tesla
TSLA
+4.34%
MicroStrategy
MSTR
+4.20%
MARA Holdings
MARA
+0.66%
Apple
AAPL
+0.07%
Microsoft
MSFT
-0.51%

Unlock the Full List